Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.
Place a direct purchase order on this report @ http://www.orbisresearch.com/contact/purchase/146183 .
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 13, 1, 49 and 8 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively for Idiopathic Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Request a sample of Idiopathic Pulmonary Fibrosis – Pipeline Review, H2 2016
– The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
– The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AdAlta Pty Ltd.
Aeolus Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc.
Apellis Pharmaceuticals Inc
ARMO Biosciences, Inc.
Asahi Kasei Pharma Corp.
BiOrion Technologies B.V.
Bristol-Myers Squibb Company
Chrysalis Pharma SAS
Cynata Therapeutics Limited
F. Hoffmann-La Roche Ltd.
Global Blood Therapeutics, Inc.
GNI Group Ltd.
HEC Pharm Co., Ltd.
Immunomet Therapeutics, Inc.
Isarna Therapeutics GmbH
Kadmon Corporation, LLC
Kasiak Research Private Limited
Kolltan Pharmaceuticals, Inc.
Kyorin Pharmaceutical Co., Ltd.
Lung Therapeutics Inc
Moerae Matrix, Inc.
ProMetic Life Sciences Inc.
Respira Therapeutics Inc
Saje Pharma, LLC
Sorrento Therapeutics, Inc.
SPR Biosciences LLC
Teva Pharmaceutical Industries Ltd.
Therabron Therapeutics, Inc.
Vicore Pharma AB
Browse the complete report @ http://www.orbisresearch.com/reports/index/idiopathic-pulmonary-fibrosis-pipeline-review-h2-2016 .
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: email@example.com